“INSPAIR, A SMART SENSOR FOR INHALERS”

“Biocorp’s objective is to develop innovative solutions in order to improve treatment compliance by patients suffering from chronic diseases. Significant applications have been developed in diabetology, endocrinology and neurology with the Datapen and Easylog devices, and our new sensor Inspair also positions us in the area of chronic lung diseases which affect an increasing number of people in need of new solutions to improve compliance”, said Jacques Gardette, Biocorp’s Founder and CEO

Asthma is a chronic disease which affects the respiratory tracts: it is characterized by an inflammation and irritation of the bronchial tubes which overreact to various triggers, and causes attacks with typical identifiable symptoms: difficulty in breathing, shortness of breath, dry cough or wheezing.Asthma is a disease lived by 4 million people in France and 334 million in the world, and which can rapidly affect the patients’ daily lives if it is not carefully controlled. The compliance and monitoring of the disease are all the more necessary in that a poor management of asthma can rapidly lead to severe asthma responsible for more than 500,000 emergency hospitalization and 1,000 to 1,500 deaths every year in France. The French health insurance estimates that nearly six in ten people with asthma have inadequate control of their disease and treatment. COPD is a chronic lung disease which develops slowly and is characterized by an airway obstruction. It is different from Asthma and usually affects older people suffering from prolonged intoxication, mostly because of smoking (90%). COPD affects about 3 million people in France, and is responsible for more deaths than HIV or Influenza. A fastidious treatment follow-up with inhaler and/or bronchodilator medication is thus required to reduce symptoms and improve the patient’s quality of life.